Table 3.
Detailed clinical characteristics of 17 patients with disease progression or relapsed primary pulmonary MALT lymphoma
| Patient | Modified Ann Arbor stage | Initial treatment | Initial treatment response | Follow-up | Salvage treatment | Final outcomes | Clinical outcomes |
|---|---|---|---|---|---|---|---|
| 1 | Stage IE | Observation | SD | Disease progression | R-CVP | CR | Alive |
| 2 | Stage IE | Observation | SD | N/A | N/A | N/A | Remains in SD (follow-up duration of 24.1 months) |
| 3 | Stage IIE | CHOP | CR | Relapse (lung, RLL, and LUL) | BR | CR | Alive |
| 4 | Stage III | CHOP | PR | Relapse (mediastinum and gastric) | BSC | PD | Expired due to disease progression |
| 5 | Stage IE | CVP | CR | Relapse (lung, RLL) | CHOP | CR | Alive |
| 6 | Stage IIE | CVP | CR | Relapse (mediastinum and liver) | CHOP and ASCT | CR | Alive |
| 7 | Stage IV | R-CVP | PR | N/A | N/A | N/A | Expired due to CHB aggravation |
| 8 | Stage III | R-CVP | PR | Disease progression | BR | CR | Alive |
| 9 | Stage IV | R-CVP | PD | Disease progression | DLICE→ESHAP and ASCT | CR | Alive |
| 10 | Stage III | R-CVP | CR | Relapse (mediastinum) | N/A | N/A | Remains in SD (follow-up duration of 28.8 months) |
| 11 | Stage IV | R-CVP | CR | Relapse (lung, LLL, and LNs) | BR | CR | Alive |
| 12 | Stage IV | R-CVP | CR | Relapse (lung, RLL) | VATS wedge resection | CR | Alive |
| 13 | Stage IV | R-CVP | CR | Relapse (both lung and tonsil) | DLICE | CR | Alive |
| 14 | Stage III | R-CVP | PR | Relapse (lung, RUL) | N/A | SD | Alive |
| 15 | Stage IV | R-CVP | PR | Relapse (lung, LLL) | VATS wedge resection | CR | Alive |
| 16 | Stage IV | R-CVP | PR | Disease progression | DHAP→Zevalin | CR | Alive |
| 17 | Stage III | R-CVP | PD | Disease progression | DLICE→DHAP→BR→ESHAP→EPOCH | SD | Alive |
ASCT, autologous hematopoietic stem cell transplantation; BR, bendamustine and rituximab; BSC, best supportive care; CHB, chronic hepatitis B infection; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete remission; CVP, cyclophosphamide, vincristine, and prednisone; DHAP, dexamethasone, high-dose cytarabine, cisplatin; DLICE, dexamethasone, l-asparaginase, ifosfamide, carboplatin, etoposide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, cisplatin; PR, partial remission; PD, progressive disease; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; SD, stable disease; VATS, video-assisted thoracic surgery.